Form 4 for TVTX Travere Therapeutics, Inc.

Accepted 2022-02-02 00:00:00 ET · period of report 2022-01-31 · accession 0001209191-22-006357 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2022-02-02	2022-01-31	TVTX	Dube Eric M	CEO, Dir	A - Grant	$0.00	+37.8K	169.6K	+29%	$0
D	2022-02-02	2022-01-31	TVTX	Dube Eric M	CEO, Dir	S - Sale	$27.40	-4,813	164.7K	-3%	-$131.9K
DM	2022-02-02	2022-01-31	TVTX	Dube Eric M	CEO, Dir	A - Grant	$0.00	+207.4K	37.8K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2022-01-31	A	A	37,848	$0.00	169,558	D	—	—
2	Common	Common Stock	2022-01-31	S	D	4,813	$27.40	164,745	D	—	—
3	Derivative	Employee stock option (right to buy)	2022-01-31	A	A	169,552	$0.00	169,552	D	$27.50 · — to 2032-01-30	169,552 Common Stock	(F3) One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.
4	Derivative	Performance-based restricted stock units	2022-01-31	A	A	37,848	$0.00	37,848	D	— · — to —	37,848 Common Stock	(F4) Each performance-based restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. (F5) This grant will vest upon the achievement of specified clinical/regulatory and commercial milestones, provided, however, if either vesting event occurs before the date that is 12 months after the date of grant, then the portion of the award that would have vested upon such event will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 to the extent the specified performance based milestones are not achieved by such date.